CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation

Pharmacogenomics

Volumn 11, Issue 5, 2010, Pages 703-714

  Capron, Arnaud ^a   Mourad, Michel ^a   De Meyer, Martine ^a   De Pauw, Luc ^a   Eddour, Djamila Chaib ^a   Latinne, Dominique ^a   Elens, Laure ^a   Haufroid, Vincent ^a   Wallemacq, Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

ABCB1; CYP3A5; Peripheral blood mononuclear cell; Pharmacogenetics; Polymorphism; Tacrolimustransplantation

Indexed keywords

CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; EXON; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRON; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BLOOD CELLS; CYTOCHROME P-450 CYP3A; EXONS; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRONS; KIDNEY TRANSPLANTATION; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH; TACROLIMUS;

EID: 77951608465     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.43     Document Type: Article

References (45)

1. Denton MD, Magee CC, Sayegh MH: Immunosuppressive strategies in transplantation. Lancet 353(9158), 1083-1091 (1999).
2. Scott LJ, McKeage K, Keam SJ, Plosker GL: Tacrolimus: a further update of its use in management of organ transplantation. Drugs 63(12), 1247-1297 (2003).
3. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in organ transplantation. Clin. Pharmacokinet. 43(10), 623-653 (2004).
4. Jusko WJ, Thomson AW, Fung J et al.: Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther. Drug Monit. 17(6), 606-614 (1995).
5. Sandborn WJ, Lauson GM, Cody TJ et al.: Early cellular rejection after orthotopic liver transplantation correlates with low concentration of FK506 in hepatic tissue. Hepatology 21(1), 70-76 (1995).
6. Sandborn WJ, Lawson GM, Krom RA, Wiesner RH: Hepatic allograft cyclosporine concentation is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology 15(6), 1086-1091 (1992).
7. Capron A, Lerut J, Verbaandert C et al.: Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther. Drug Monit. 29(3), 340-348 (2007).
8. MacPhee IA, Fredericks S, Tai T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002).
9. Zheng HX, Webber S, Zeevi A et al.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3(6), 477-483 (2003).
10. Anglicheau D, Vertuyft C, Laurent-Puig P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14(7), 1889-1896 (2003).
11. Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol Ther. 74(3), 245-254 (2003).
12. Thervet E, Anglicheau D, King B et al.: Impact of cytochrome P4503A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8), 1233-1235 (2003).
13. Haufroid V, Mourad M, van Kerckhove V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004).
14. Mourad M, Wallemacq P, De Meyer M et al.: Biotansformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 85(Suppl. 7), S19-S24 (2008).
15. Elens L, Capron A, Kerckhove VV et al.: 1199GA and 2677GT/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics 17(10), 873-883 (2007).
16. Crettol S, Venetz JP, Fontana M et al.: Infuence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18(4), 307-315 (2008).
17. Kandem LK, Streit F, Zanger UM et al.: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 51(8), 1374-1381 (2005).
18. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
19. Hustert E, Habrel M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773-779 (2001).
20. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporine A and FK506. J. Biol. Chem. 268(9), 6077-6080 (1993).
21. Callaghan R, Crowley E, Potter S, Kerr ID: P-glycoprotein: so many ways to turn it on. J. Clin. Pharmacol. 48(3), 365-378 (2008).
22. Coons JS, Wang YZ, Bines SD, Markham PN, Chong AS, Gebel HM: Multidrug resistance P-glycoprotein in human lymphocytes. Hum. Immunol. 32(2), 134-140 (1991).
23. Chaudhray PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80(11), 134-140 (1992).
24. Kim RB, Leake BF, Choo EF et al.: Identifcation of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
25. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435CT affects mRNA stability. Pharamcogenet. Genomics 15(10), 693-704 (2005).
26. Kimchy-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specifcity. Science 315(5811), 525-528 (2007).
27. Hesselink DA, van Gelder T, van Schaik RH: The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6(4), 323-337 (2005).
28. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ: MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19(15), 1617-1625 (2005).
29. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ: Multidrug resistance gene G1199A polymorphism alters effux transport activity of P-glycoprotein. J. Pharmacol. Exp. Ther. 310(3), 1199-1207 (2004).
30. Crouthamel MH, Wu D, Yang Z, Ho RJ: A novel MDR1 G1199A variant alters drug resistance and effux transport activity of P-glycoprotein in recombinant Hek cells. J. Pharm. Sci. 95(12), 2767-2777 (2006).
31. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol Ther. 75(1), 13-33 (2004).
32. Wallemacq P, Goffnet JS, O'Morchoe S et al.: Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther. Drug Monit. 31(2), 198-204 (2009).
33. Capron A, Musuamba F, Latinne D et al.: Validation of a liquid chromatography mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther. Drug Monit. 31(2), 178-186 (2009).
34. Mai I, Perloff ES, Bauer S et al.: MDR1 haplotypes derived from exon 21 and 26 do not affect the steady state pharmacokinetics of tacrolimus in renal transplant patients. Br. J. Pharmacol. 58(5), 548-553 (2004).
35. Tsuchiya N, Satoh S, Tada H et al.: Infuence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78(8), 1182-1187 (2004).
36. Yu S, Wu L, Jin J et al.: Infuence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81(1), 46-51 (2006).
37. Wei-lin W, Jing J, Shu-sen Z et al.: Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transplant. 12(5), 775-780 (2006).
38. Goto M, Musuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14(7), 471-478 (2004).
39. Mourad M, Wallemacq P, De Meyer M et al.: The infuence of genetic polymorphism of cytochrome P4503A5 and MDR1 (ABCB1) on the starting dose-adjusted tacrolimus through concentrations after kidney transplantation in relation to renal function. Clinical Chemistry Laboratories Medicine 44(10), 1192-1198 (2006).
40. + natural killer cells. Pharmacogenetics 11(4), 293-298 (2001).
41. Drescher S, Schaeffeler E, Hitzl M et al.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53(5), 526-534 (2002).
42. Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: pharmacogenetics study. Lancet 359(9300), 30-36 (2002).
43. Beysens AJ, Wijnene RM, Beuman GH, van der Heyden J, Kootstra G, van As H: FK506: monitoring in plasma or whole blood? Transplant. Proc. 23(6), 2745-2747 (1991).
44. Machida M, Takahara S, Ishibashi M, Hayashi M, Sekihara T, Yamanaka H: Effect of temperature and haematocrit on plasma concentration of FK506. Transplant. Proc. 23(6), 2753-2754 (1991).
45. Nagase K, Iwasaki K, Nozaki K, Noda K: Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J. Pharm. Pharmacol. 46(2), 113-117 (1994).